KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Restructuring Costs (2016 - 2018)

Vertex Pharmaceuticals (VRTX) has 10 years of Restructuring Costs data on record, last reported at $4000.0 in Q4 2018.

  • For Q4 2018, Restructuring Costs fell 98.97% year-over-year to $4000.0; the TTM value through Sep 2019 reached $4000.0, down 99.3%, while the annual FY2018 figure was -$184000.0, 101.29% down from the prior year.
  • Restructuring Costs reached $4000.0 in Q4 2018 per VRTX's latest filing, down from $174000.0 in the prior quarter.
  • Across five years, Restructuring Costs topped out at $40.8 million in Q3 2014 and bottomed at -$3.3 million in Q1 2015.
  • Average Restructuring Costs over 5 years is $3.4 million, with a median of $365000.0 recorded in 2016.
  • Peak YoY movement for Restructuring Costs: skyrocketed 15766.67% in 2014, then crashed 152.88% in 2015.
  • A 5-year view of Restructuring Costs shows it stood at $4.2 million in 2014, then tumbled by 63.4% to $1.5 million in 2015, then tumbled by 85.3% to $224000.0 in 2016, then skyrocketed by 72.77% to $387000.0 in 2017, then plummeted by 98.97% to $4000.0 in 2018.
  • Per Business Quant database, its latest 3 readings for Restructuring Costs were $4000.0 in Q4 2018, $174000.0 in Q3 2018, and -$62000.0 in Q2 2018.